Company Details
  • Taizhou Volsen Chemical Co., Ltd.

  •  [Zhejiang,China]
  • Business Type:Manufacturer
  • Main Mark: Americas , Asia , East Europe , Europe , North Europe , Other Markets , West Europe , Worldwide
  • Exporter:91% - 100%
  • Certs:GS, CE, ISO9001, ISO14000
  • Description:DOT1L Enzyme Inhibitor EPZ5676 CAS1380288-87-8,Anti Tumor New Drug EPZ-5676 1380288-87-8,EPZ-5676 CAS 1380288-87-8
Taizhou Volsen Chemical Co., Ltd. DOT1L Enzyme Inhibitor EPZ5676 CAS1380288-87-8,Anti Tumor New Drug EPZ-5676 1380288-87-8,EPZ-5676 CAS 1380288-87-8
Home > Products > Active Pharmaceutical Ingredients > Leukemia Treatment EPZ-5676 Cas Number 1380288-87-8

Leukemia Treatment EPZ-5676 Cas Number 1380288-87-8

Share to:  
    Unit Price: USD 100 / Kilogram
    Payment Type: L/C,T/T
    Incoterm: CIF
    Min. Order: 1 Kilogram
    Delivery Time: 3 Days

Basic Info

Model No.: 1380288-87-8

Additional Info

Packaging: 25KGS/DRUM

Productivity: 30T/Y


Transportation: Ocean,Land,Air

Place of Origin: CHINA

Supply Ability: 30T/Y

Certificate: YES

Product Description

EPZ-5676 CAS number is 1380288-87-8, a new drug for the treatment of a rare subtype of leukemia EPZ-5676 is recognized by the FDA as a rare disease. The drug is currently in Phase I clinical studies. Affected by this news, the company's stock price also rose.EPZ-5676 CAS number 1380288-87-8 is an inhibitor of an enzyme called DOT1L. DOT1L plays an important role in the pathogenesis of mixed cell line leukemia. Epizyme has authorized Celgene to own the EPZ-5676 sales rights outside the US market.
According to the FDA's rules for rare disease medications, diseases with a patient count of less than 200,000 can be defined as rare diseases, compared with approximately 5,000 patients with mixed cell line leukemia. Epizyme's EPZ-5676 study will receive a series of preferential measures such as tax cuts after qualifying for the rare disease drug.
EP-5676 is a competitive inhibitor of S-adenosylmethionine (SAM) of protein methyltransferase DOT1L with a Ki of 80 pM, which is more than 37,000 more selective than all other PMTs, inhibiting tumor H3K79 methylation. . Phase 1.EPZ-5676 reduced H3K79 dimethylation in MV4-11 cells with an IC50 of 2.6 nM. EPZ-5676 reduces H3K79 methylation in a concentration- and time-dependent manner, but has no effect on other histone sites, which results in a MLL gene and selective apoptotic cell killing of key targets that are inhibited in MLL rearranged leukemia cells. EPZ-5676 inhibited the proliferation of the MLL-AF4 rearranged cell line MV4-11 with an IC50 of 9 nM.
In a MLL rearranged leukemia xenograft model, EPZ-5676 resulted in a dose-dependent anti-tumor activity after a continuous intravenous infusion for 21 days. At the highest dose of 70.5 mg / kg / day, the treatment stopped after the tumor completely resolved, and there was no tumor regrowth for up to 32 days. No significant weight loss or significant toxicity occurred in the EPZ-5676 treated rats.

Thera. Category:Anti-cancer

Cas No.: 1380288-87-8


Molecular Formula:C30H42N8O3


Molecular Weight:562.70628

Pharmacopeia: in house spe.

Specifications:Available on request

Packing:Export worthy packing

Material Safety Data Sheet:Available on request

Looking for ideal DOT1L Enzyme Inhibitor EPZ5676 CAS1380288-87-8 Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the Anti Tumor New Drug EPZ-5676 1380288-87-8 are quality guaranteed. We are China Origin Factory of EPZ-5676 CAS 1380288-87-8. If you have any question, please feel free to contact us.

Product Categories : Active Pharmaceutical Ingredients

Product Images
  • Leukemia Treatment EPZ-5676 Cas Number 1380288-87-8
Email to this supplier
  • *Subject:
  • *Messages:
    Your message must be between 20-8000 characters
Copyright © 2019 Taizhou Volsen Chemical Co., Ltd. All rights reserved.
Communicate with Supplier?Supplier
Amy Cheng Ms. Amy Cheng
What can I do for you?